AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22093035 — intervention group
Group type: COMPARATOR
Intervention: 0% CA (Control)
Number of subjects: 1720
Study 21130382 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg oral immunotherapy (OIT) with individualized dosing based on egg white IgE levels
Number of subjects: 6
Study 17687955 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured preventive programme
Number of subjects: 31
Study 17687955 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 31
Study 17687955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 31
Study 17687955 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 31
Study 15576394 — intervention group
Group type: EXPERIMENTAL
Intervention: COC and metformin (1500 mg/day) for 6 months
Number of subjects: 30
Study 15576394 — intervention group
Group type: COMPARATOR
Intervention: COC alone for 6 months
Number of subjects: 30
Study 11914249 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 2607
Study 9789335 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 msw dive group
Number of subjects: 24
Study 9789335 — intervention group
Group type: COMPARATOR
Intervention: 0.5 msw dive group
Number of subjects: 24
Study 7623902 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (protocol 1)
Number of subjects: 921
Study 7623902 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and glyburide (protocol 2)
Number of subjects: 921
Study 7623902 — intervention group
Group type: COMPARATOR
Intervention: Glyburide (protocol 2)
Number of subjects: 921
Study 7623902 — intervention group
Group type: COMPARATOR
Intervention: Control groups (placebo and glyburide)
Number of subjects: 921
Study 2717986 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical thrombin
Number of subjects: 123
Study 2717986 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 123
Study 347464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydergine
Number of subjects: 1300
Study 31415033 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus (mTOR inhibitor)
Number of subjects: 8
Study 31415033 — intervention group
Group type: COMPARATOR
Intervention: belatacept
Number of subjects: 8
Study 31468172 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hypoxia (fraction of inspired oxygen = 12.9%)
Number of subjects: 14
Study 31468172 — intervention group
Group type: COMPARATOR
Intervention: Blood flow restriction (BFR) at 0%, 45%, or 60% of resting arterial occlusion pressure
Number of subjects: 14
Study 31468172 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (fraction of inspired oxygen = 20.9%)
Number of subjects: 14
Study 31468172 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perceived discomfort, difficulty breathing, and limb discomfort
Number of subjects: 14
Study 28701367 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ACVBP
Number of subjects: 211
Study 28701367 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP14
Number of subjects: 211
Study 28701367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 211
Study 26116458 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adiponectin levels
Number of subjects: 172
Study 26116458 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1C and low-density lipoprotein
Number of subjects: 172
Study 23869233 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg kg(-1) day(-1))
Number of subjects: 21
Study 23869233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 21
Study 20667989 — intervention group
Group type: EXPERIMENTAL
Intervention: surface-modified double-lumen catheter (smDLC)
Number of subjects: 236
Study 20667989 — intervention group
Group type: COMPARATOR
Intervention: standard double-lumen catheter (sDLC)
Number of subjects: 236
Study 19247018 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA enriched enteral nutrition (2.2 g EPA/d for 5 days preoperatively and 21 days postoperatively)
Number of subjects: 53
Study 19247018 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 53
Study 19247018 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA enriched enteral nutrition
Number of subjects: 53
Study 16461311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent subcutaneous high-dose IL-2
Number of subjects: 40
Study 16461311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent subcutaneous low-dose IL-2
Number of subjects: 40
Study 16461311 — intervention group
Group type: COMPARATOR
Intervention: Control group (ART only)
Number of subjects: 40
Study 16398654 — intervention group
Group type: EXPERIMENTAL
Intervention: New index predicting response to plasma exchange
Number of subjects: 171
Study 16398654 — intervention group
Group type: COMPARATOR
Intervention: Rose index of TTP/HUS severity
Number of subjects: 171
Study 12829196 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (1000 microg/min)
Number of subjects: 8
Study 12829196 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (3 microg/min)
Number of subjects: 8
Study 12829196 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat in the presence of Indomethacin
Number of subjects: 8
Study 12829196 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 10365634 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/d)
Number of subjects: 5
Study 10365634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (75 mg/d)
Number of subjects: 5
Study 8963484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexniguldipine (750 mg/d, 1,500 mg/d, 2,250 mg/d) for 3 consecutive weeks
Number of subjects: 14
Study 8963484 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexniguldipine (2 mg/kg body weight)
Number of subjects: 14
Study 8963484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexniguldipine
Number of subjects: 14
Study 1882877 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis model plus drug therapy review (experimental group)
Number of subjects: 340
Study 1882877 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy review alone (control group)
Number of subjects: 340
Study 31618266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuevo Amanecer-II (NA-II) intervention, 10 weeks duration, includes stress management videos, healthy lifestyles information, survivorship information, and skills practice.
Number of subjects: 153
Study 31618266 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 153
Study 28079729 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium animalis subsp lactis and Lactobacillus rhamnosus, 10 billion colony-forming units, 50:50)
Number of subjects: 400
Study 28079729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 26659582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 μg bid)
Number of subjects: 50
Study 26659582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23399032 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion Programme (PAPP) for 60 minutes, twice a week during three months
Number of subjects: 100
Study 23399032 — intervention group
Group type: COMPARATOR
Intervention: Health education (control group)
Number of subjects: 100
Study 23399032 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion Programme (PAPP)
Number of subjects: 100
Study 21697535 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 4.5 g/d
Number of subjects: 85
Study 21697535 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil
Number of subjects: 85
Study 21697535 — intervention group
Group type: COMPARATOR
Intervention: Heated safflower oil
Number of subjects: 85
Study 21697535 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 85
Study 19128672 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole daily
Number of subjects: 40
Study 19128672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 40
Study 16229059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution magic angle spinning (HR MAS) MR spectroscopy of breast cancer tissue
Number of subjects: 85
Study 16229059 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) of MAS spectra
Number of subjects: 85
Study 12614313 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (1:10 conversion ratio)
Number of subjects: 20
Study 12614313 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (1:5 conversion ratio)
Number of subjects: 20
Study 12614313 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (baseline)
Number of subjects: 20
Study 10869264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan (1.5, 3.0, or 6.0 mg/kg)
Number of subjects: 48
Study 10869264 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Number of subjects: 48
Study 10869264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8603442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin 20 mg
Number of subjects: 12
Study 8603442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin 12.5 mg
Number of subjects: 12
Study 8603442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin 6.5 mg
Number of subjects: 12
Study 8603442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin (all doses)
Number of subjects: 12
Study 8603442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin (doses 6.5 to 12.5 mg)
Number of subjects: 12
Study 8603442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical idarubicin
Number of subjects: 12
Study 1413921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 182
Study 1413921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 182
Study 1413921 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH-related hormones
Number of subjects: 182
Study 1413921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol
Number of subjects: 182
Study 1413921 — intervention group
Group type: COMPARATOR
Intervention: Corticotropin releasing-hormone
Number of subjects: 182
Study 1413921 — intervention group
Group type: COMPARATOR
Intervention: Cholecystokinin
Number of subjects: 182
Study 6368241 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) given i.v. in 4 doses of 1 mg/kg over a period of 4 1/2 hr
Number of subjects: 35
Study 6368241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethazone (DXM) administered i.m. in 4 doses of 8 mg over 24 hr and another 10 mg i.v. just prior to CDDP administration
Number of subjects: 35
Study 6368241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) given to 16 patients who expressed a positive opinion on both previous antiemetics
Number of subjects: 35
Study 31272294 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a police uniform
Number of subjects: 0
Study 31272294 — intervention group
Group type: COMPARATOR
Intervention: Control group (not wearing a police uniform)
Number of subjects: 0
Study 30514352 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly one-hour multi-component training session within a WHPP over a one-year period
Number of subjects: 9
Study 27259354 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NC0)
Number of subjects: 56
Study 27259354 — intervention group
Group type: EXPERIMENTAL
Intervention: 50μg chromium nicotinate (NC50)
Number of subjects: 56
Study 27259354 — intervention group
Group type: EXPERIMENTAL
Intervention: 200μg chromium nicotinate (NC200)
Number of subjects: 56
Study 23996739 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone syrup 0.15 mL/kg three times a day for 3 months along with PEG solution 0.6 g/kg/day two times a day for 6 months
Number of subjects: 105
Study 23996739 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months along with PEG solution 0.6 g/kg/day two times a day for 6 months
Number of subjects: 105
Study 22610495 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM-to-CCHT (n=23)
Number of subjects: 150
Study 22610495 — intervention group
Group type: EXPERIMENTAL
Intervention: ACM-to-CC (n=21)
Number of subjects: 150
Study 22610495 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-to-CC (n=28)
Number of subjects: 150
Study 22610495 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-to-UC (n=29)
Number of subjects: 150
Study 20718174 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated dose based on gland size
Number of subjects: 128
Study 20718174 — intervention group
Group type: COMPARATOR
Intervention: Calculated dose based on gland size and 24‐hour 131I uptake
Number of subjects: 128
Study 20718174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study 19055280 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Changqiang (GV 1) and Chengshan (BL 57) with sparse‐dense wave, frequency 2/100 Hz for 5 days
Number of subjects: 120
Study 19055280 — intervention group
Group type: COMPARATOR
Intervention: Medication group with oral Tramadol and rectal Mayinglong Shexiang Zhichuang Suppository for 5 days
Number of subjects: 120
Study 19055280 — intervention group
Group type: COMPARATOR
Intervention: Comparison between electroacupuncture and medication groups
Number of subjects: 120
Study 15779040 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition F-NF (fat before nonfat)
Number of subjects: 8
Study 15779040 — intervention group
Group type: COMPARATOR
Intervention: Condition NF-F (nonfat before fat)
Number of subjects: 8
Study 15779040 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition F-NF
Number of subjects: 8
Study 15779040 — intervention group
Group type: COMPARATOR
Intervention: Condition NF-F
Number of subjects: 8
Study 14988669 — intervention group
Group type: EXPERIMENTAL
Intervention: a-interferon (a-IFN)
Number of subjects: 154
Study 14988669 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon (considered for future treatment)
Number of subjects: 154
Study 12476366 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded compression leg bandages (LB)
Number of subjects: 54
Study 12476366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent electric calf muscle stimulation (IECS)
Number of subjects: 54
Study 12476366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 54
Study 12476366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 10519475 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training for 6 months
Number of subjects: 0
Study 10519475 — intervention group
Group type: COMPARATOR
Intervention: Control group (athletes/runners)
Number of subjects: 0
Study 7747681 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responders (requested medical assistance < 60 minutes after symptom onset)
Number of subjects: 501
Study 7747681 — intervention group
Group type: EXPERIMENTAL
Intervention: Early responders
Number of subjects: 501
Study 7747681 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmarried patients
Number of subjects: 501
Study 7747681 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients experiencing symptoms at work
Number of subjects: 501
Study 2153435 — intervention group
Group type: EXPERIMENTAL
Intervention: BTOC regimen
Number of subjects: 103
Study 2153435 — intervention group
Group type: EXPERIMENTAL
Intervention: VP‐16/CDDP regimen
Number of subjects: 103
Study 2153435 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 103
Study 2153435 — intervention group
Group type: EXPERIMENTAL
Intervention: BTOC good risk patients
Number of subjects: 103
Study 2153435 — intervention group
Group type: EXPERIMENTAL
Intervention: BTOC poor risk patients
Number of subjects: 103
Study 2153435 — intervention group
Group type: EXPERIMENTAL
Intervention: VP‐16/CDDP good risk patients
Number of subjects: 103
Study 2153435 — intervention group
Group type: EXPERIMENTAL
Intervention: VP‐16/CDDP poor risk patients
Number of subjects: 103
Study 2153435 — intervention group
Group type: COMPARATOR
Intervention: VP‐16/CDDP vs BTOC for good risk patients
Number of subjects: 103
Study 6273009 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 20
Study 6273009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31542082 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg per week starting from the first day after menstruation
Number of subjects: 188
Study 31542082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 31542082 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 188
Study 28316003 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammaplex 10%
Number of subjects: 48
Study 28316003 — intervention group
Group type: COMPARATOR
Intervention: Gammaplex 5%
Number of subjects: 48
Study 26417701 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time CPR visual feedback during cardiac arrest
Number of subjects: 1605
Study 26417701 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-Time CPR training
Number of subjects: 1605
Study 26417701 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1605
Study 24600231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantethine (600 mg/day from weeks 1 to 8 and 900 mg/day from weeks 9 to 16)
Number of subjects: 32
Study 24600231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24600231 — intervention group
Group type: COMPARATOR
Intervention: Pantethine and Placebo
Number of subjects: 32
Study 22533799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-chewing group (chewing xylitol-containing gum twice a day for 15 min; n = 95)
Number of subjects: 186
Study 22533799 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum; n = 91)
Number of subjects: 186
Study 22533799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-chewing group
Number of subjects: 186
Study 22533799 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study 19866350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐peak
Number of subjects: 14
Study 19866350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐dslope
Number of subjects: 14
Study 19866350 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐on
Number of subjects: 14
Study 17697903 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release metformin (MER) plus sulfonylurea (glyburide)
Number of subjects: 741
Study 17697903 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea monotherapy
Number of subjects: 741
Study 15064265 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 459
Study 15064265 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 100 mg
Number of subjects: 459
Study 15064265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 11379168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling intervention (decreasing temperature by 3 degrees C)
Number of subjects: 0
Study 11379168 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9506323 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal from digoxin therapy
Number of subjects: 0
Study 9506323 — intervention group
Group type: COMPARATOR
Intervention: Continued use of digoxin
Number of subjects: 0
Study 8039909 — intervention group
Group type: EXPERIMENTAL
Intervention: 22, 11, or 5.5 micrograms of the conjugated A‐C vaccine
Number of subjects: 50
Study 8039909 — intervention group
Group type: COMPARATOR
Intervention: Approved meningococcal vaccine
Number of subjects: 50
Study 8039909 — intervention group
Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 50
Study 2525975 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 0
Study 2525975 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 29326331 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen therapy (LFO2) for 2 months
Number of subjects: 20
Study 29326331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VRT and chemosensitivity in logistic regression model
Number of subjects: 20
Study 27190087 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin plus pioglitazone 15 mg
Number of subjects: 936
Study 27190087 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin plus pioglitazone 30 mg
Number of subjects: 936
Study 27190087 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin plus pioglitazone 45 mg
Number of subjects: 936
Study 27190087 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin monotherapy
Number of subjects: 936
Study 27190087 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone monotherapy
Number of subjects: 936
Study 23790011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 1105
Study 23790011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/day
Number of subjects: 1105
Study 23790011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1105
Study 22409999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin administration to keep blood glucose between 6 and 8 mmol/l during surgery (n = 9)
Number of subjects: 20
Study 22409999 — intervention group
Group type: COMPARATOR
Intervention: Control group received insulin if blood glucose >14 mmol/l (n = 8)
Number of subjects: 20
Study 22409999 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin administration (n = 9)
Number of subjects: 20
Study 22409999 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 20
Study 20959577 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil capsules (800 mg/d of DHA)
Number of subjects: 2399
Study 20959577 — intervention group
Group type: COMPARATOR
Intervention: Vegetable oil capsules without DHA (control)
Number of subjects: 2399
Study 18954193 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 139